Długoterminowa skuteczność azacytydyny u chorej z ostrą białaczką szpikową na podłożu zmian dysplastycznych

Q4 Medicine

Hematologia Pub Date : 2019-10-02 DOI:10.5603/hem.2019.0004

M. Wójtowicz

引用次数: 0

Abstract

Azacitidine is a hypomethylating agent, commonly used in treatment of acute myeloid leukemia with 20–30% bone marrow blasts. We present a case of a long-term efficacy of this drug used in the patient for 36 months.

查看原文本刊更多论文

阿扎胞苷是一种低甲基化药物，常用于治疗骨髓原细胞占20-30%的急性髓性白血病。我们提出了一个病例的长期疗效的这种药物在病人使用了36个月。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematologia Medicine-Oncology

自引率

0.00%

发文量

审稿时长

4 weeks

期刊介绍： Hematology is the quarterly under auspices of the Institute of Hematology and Transfusion Medicine. The journal is addressed to hematologists, oncologists and also internists. It contains the overview/review articles, case reports, essays, including reports from the scientific and educational conferences as well as test questions on hematology. Journal of the Institute of Hematology and Transfusiology.